Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
GM-2505 by Gilgamesh Pharmaceuticals for Major Depressive Disorder: Likelihood of Approval
GM-2505 is under clinical development by Gilgamesh Pharmaceuticals and currently in Phase II for Major Depressive Disorder. According to GlobalData,...
Data Insights
GM-2505 by Gilgamesh Pharmaceuticals for Anxiety Disorders: Likelihood of Approval
GM-2505 is under clinical development by Gilgamesh Pharmaceuticals and currently in Phase II for Anxiety Disorders. According to GlobalData, Phase...